Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients
AffiliationDepartment of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
MetadataShow full item record
AbstractBackground: We used a structured approach to validate chemotherapy information derived from a national routinely collected chemotherapy dataset and from national administrative hospital data. Methods: 10,280 patients who had surgical resection with stage III colon cancer were included. First, we compared information derived from the national chemotherapy dataset (SACT) and from the administrative hospital dataset (HES) in the English NHS with respect to receipt of adjuvant chemotherapy (ACT). Second, we compared regimen and number of cycles in linked patient-level records. Third, we carried out a sensitivity analysis to establish to what extent the impact of ACT receipt differed according to data source. Results: 6,012 patients (58 %) received ACT according to either dataset. Of these patients, 3,460 (58 %) had ACT records in both datasets, 1,649 (27 %) in SACT alone, and 903 (15 %) in HES alone. Of the 3,460 patients with records in both datasets, 3,320 (96 %) had matching regimens. There was good agreement on cycle number with similar proportions of patients recorded with a single cycle (6 % in SACT vs. 7 % in HES) and slightly fewer patients recorded with more than 8 cycles in SACT (32 % in SACT vs. 35 % in HES). 3-year cancer-specific mortality was similar for patients receiving ACT, regardless of whether a patient received ACT according to SACT alone (16.6 %), according to HES alone (16.8 %), or according to either SACT or HES (17.1 %). Conclusion: Routinely collected national chemotherapy data and administrative hospital data are highly accurate in recording regimen and number of chemotherapy cycles. However, chemotherapy information should ideally be captured from both datasets to avoid under-capture, particularly of oral chemotherapy from administrative hospital data, and to minimise bias.
CitationBoyle JM, Kuryba A, Braun MS, Aggarwal A, van der Meulen J, Cowling TE, et al. Validity of chemotherapy information derived from routinely collected healthcare data: A national cohort study of colon cancer patients. Cancer Epidemiology. 2021 Aug;73:101971.
- Consistency of recording of chemotherapy cycles in the National Cancer Registration and Analysis Service Systemic Anti-Cancer Therapy database and the Hospital Episode Statistics Admitted Patient Care database.
- Authors: McDonald L, Sammon C, Carroll R, Harish A, C AS, Tyas D, Ramagopalan SV
- Issue date: 2020 Jan
- Determinants of Variation in the Use of Adjuvant Chemotherapy for Stage III Colon Cancer in England.
- Authors: Boyle JM, Kuryba A, Cowling TE, Aggarwal A, Hill J, van der Meulen J, Walker K, Braun MS
- Issue date: 2020 May
- 30-day mortality after systemic anticancer treatment for breast and lung cancer in England: a population-based, observational study.
- Authors: Wallington M, Saxon EB, Bomb M, Smittenaar R, Wickenden M, McPhail S, Rashbass J, Chao D, Dewar J, Talbot D, Peake M, Perren T, Wilson C, Dodwell D
- Issue date: 2016 Sep
- Risk of Post-Discharge Venous Thromboembolism and Associated Mortality in General Surgery: A Population-Based Cohort Study Using Linked Hospital and Primary Care Data in England.
- Authors: Bouras G, Burns EM, Howell AM, Bottle A, Athanasiou T, Darzi A
- Issue date: 2015
- The effect of comorbidity on the use of adjuvant chemotherapy and type of regimen for curatively resected stage III colon cancer patients.
- Authors: Hsieh MC, Thompson T, Wu XC, Styles T, O'Flarity MB, Morris CR, Chen VW
- Issue date: 2016 May